logo

Department Research

Research in the Department of Neurology has grown by leaps and bounds in recent years.  Between FY14 and FY16, the total sponsored research dollars grew by over 180%.  Total research dollars awarded in FY16 topped $4.8 million.

 

   

Basic Science
Our basic science laboratories are helping to advance the understanding of neurodegenerative disease, multiple sclerosis, and epilepsy, which will lead the way towards innovative translational research in the future.  In FY16, the Department received over $800,000 in basic science research awards from the National Institute of Neurological Disorders and Stroke at NIH.

Clinical Research and Clinical Trials
The Department of Neurology has a very active clinical research program with ongoing clinical trials in Parkinson’s disease, Stroke, Epilepsy, Neuro-oncology and Multiple Sclerosis.

 

Active Projects in Department of Neurology and Parkinson's Center

Project Title

Sponsor

Eye Tracking as a Biomarker for Manifest and Prodromal Parkinson's Disease

Michael J. Fox Foundation for Parkinson's Research

RQ10 for Gastroparesis and Constipation in Parkinson's Disease

Michael J. Fox Foundation for Parkinson's Research

(SURE-PD3) A randomized, double-blind, placebo-controlled treatment to slow clinical decline in early Parkinson's disease

Massachusetts General Hospital

Parathion Exposure: Mechanisms of Toxicity and Treatment

National Institute of Neurological Disorders and Stroke/NIH/DHHS

Hypothermia Reduces Mortality and Morbidity from Status Epilepticus

National Institute of Neurological Disorders and Stroke/NIH/DHHS

Novel Therapeutic Approaches for the Treatment of Depression and Cognitive Deficits in a Rodent Model of Gulf War Veterans Illness

Department of Defense

A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

Biogen Idec, Inc.

A Randomized, Double-Blind, Multinational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin(ASA) in Patients with Acute Ischaemic Stroke or TIA [SOCRATES]

Astra Zeneca

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Chugai Pharmaceutical Co. LTD

Plegridy (peginterferon B-1a) Real World Effectiveness and Safety Observational Program (POP)

Biogen Idec, Inc.

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke (MILESTONE)

Acorda Therapeutics, Inc.

(DALF-PS-1029) An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets

Acorda Therapeutics, Inc.

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Boehringer Ingelheim Pharmaceuticals, Inc.

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open-Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy with Cataplexy

INC Research, LLC

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults with Dravet Syndrome.

GW Pharmaceuticals

An Open-Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults with Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.

GW Pharmaceuticals

Cyclophilin A in CNS inflammatory disorders

National Institute of Neurological Disorders and Stroke/NIH/DHHS

A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1

inVentiv Clinical LLC

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters

inVentiv Health Inc.

Consequences of Prolonged Febrile Seizures in Childhood

Albert Einstein College of Medicine, Inc.

A Prospective Registry Study in a Global Huntington's Disease Cohort (Enroll-HD)

CHDI Foundation

Open PRIdopidine Dose Evaluation in Huntington's Disease

ICON Clinical Research, Inc.

The Dystonia Coalition Projects

Dystonia Medical Research Foundation

HDSA Centers of Excellence

Huntington's Disease Society of America, Inc.

An open label, expanded access protocol intended to provide treatment with MP-104 (deflazacort) to U.S. children, adolescents, and/or adults with Duchenne muscular dystrophy

Marathon Pharmaceuticals LLC

A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)

NS Pharma Inc.

Multi-Center, Concurrent-Controlled, On-Label Study of the NeuRx Diaphragm Pacing System (DPS) in Participants with Amyotrophic Lateral Sclerosis (ALS) PARADIGM

Synapse Biomedical, Inc.

Imaging Dementia: Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study

American College of Radiology